Aptamer Tests Face the Validation Challenge

Clinical adoption will require reproducibility, quality control, and evidence of diagnostic utility

To discuss the development and validation challenges of nucleic acid aptamers for use in molecular diagnostics.

Aptamer Development: Aptamers are developed using systematic evolution of ligands by exponential enrichment (SELEX), which involves isolating binding sequences from a large library.
New Selection Methods: Newer methods like microfluidic platforms, nuclease-assisted techniques, and hydrogel systems aim to improve selection speed and performance.
AI and Machine Learning: Artificial intelligence and machine learning are utilized to predict aptamer structures and analyze datasets.
Validation Requirements: Aptamers must undergo rigorous validation, including structure confirmation and performance testing in clinically relevant samples.
Diagnostic Platform Components: Aptamer-based diagnostics typically include an aptamer, a reporting system, and signal amplification methods.

Aptamers can bind a variety of targets and offer advantages over antibodies, such as chemical synthesis and stability.
Clinical translation of aptamers is limited due to issues like nonspecific binding and susceptibility to degradation.
Rigorous validation is required for aptamer-based tests to meet the standards of existing diagnostic technologies.

Aptamers may change shape or bind nonspecifically in complex biological samples.
Their performance can be influenced by environmental factors such as temperature and pH.
Limited routine clinical use of developed aptamers despite thousands being created.